In vivo model for evaluation of species-specific virus vaccines.
It is difficult to evaluate the protective efficacy of species-specific viruses of humans and expensive companion animals where there is no non-human animal model. This study describes an in vivo model system which allows simultaneous operation of humoral, cell-mediated, interferon-like or other unidentified immunological defence mechanisms. There was evidence of in vivo inactivation of both enveloped and unenveloped DNA and RNA viruses including retrovirus mouse sarcoma virus/mouse leukaemia virus as evaluated by assay of the enzyme reverse transcriptase. This model will allow examination of vaccine efficacy in immunocompetent host animals while avoiding morbidity and/or mortality from virus infection in these animals.
Skinner
G R
GR
Vaccine Research Foundation, Lapworth, Warwickshire, UK.
Davies
J
J
Billstrom
M A
MA
Buchan
A
A
D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D004267:DNA Viruses / Q000276:immunology*; D004686:Encephalomyocarditis virus / Q000276:immunology; D006564:Herpesviridae / Q000276:immunology; D006801:Humans; D009980:Influenza A virus / Q000276:immunology; D009052:Leukemia Virus, Murine / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D012328:RNA Viruses / Q000276:immunology*; D009053:Sarcoma Viruses, Murine / Q000276:immunology; D013539:Simian virus 40 / Q000276:immunology; D013045:Species Specificity; D014611:Vaccination; D014765:Viral Vaccines / Q000276:immunology*
D014765:Viral Vaccines